Ozempic, a medication used to manage type 2 diabetes, has a competitor in the form of a similar drug called Zeposia (generic name: semaglutide). Zeposia, also known as Zepbound in its weight-management form, has been recently approved by the FDA as a treatment for obesity, making it a direct competitor to Ozempic [2][3]. Both drugs contain the same active ingredient, semaglutide, and function in a similar way [1]. However, Zepbound/Zeposia is specifically marketed and approved for weight management, while Ozempic is primarily approved for the treatment of type 2 diabetes [2]. It is important to note that the information provided does not cover all potential competitors or comparisons between the two drugs, but it does establish Zeposia/Zepbound as a direct competitor to Ozempic in the market for weight management.

Sources:
[1] <https://www.drugpatentwatch.com/p/tradename/OZEMPIC>
[2] <https://www.rollingstone.com/culture/culture-news/zepbound-weight-loss-ozempic-medication-1234926284/>
[3] <https://www.wired.com/story/fda-approves-weight-loss-drug-zepposia-zepbound-ozempic-rival/>